Comparative Pharmacology
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus PROMETHAZINE HYDROCHLORIDE PHENYLEPHRINE HYDROCHLORIDE W CODEINE PHOSPHATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus PROMETHAZINE HYDROCHLORIDE PHENYLEPHRINE HYDROCHLORIDE W CODEINE PHOSPHATE.
ACUVUE THERAVISION WITH KETOTIFEN vs PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, sedative, and antiemetic via central dopamine D2 and muscarinic M1 receptor blockade. Phenylephrine is a sympathomimetic amine that acts as a selective α1-adrenergic receptor agonist, causing vasoconstriction. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia and antitussive effects, partly after O-demethylation to morphine.
One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.
Each 5 mL of oral solution contains promethazine hydrochloride 6.25 mg, phenylephrine hydrochloride 5 mg, and codeine phosphate 10 mg. Adult dose: 5 mL every 4 to 6 hours as needed. Maximum 30 mL per day.
None Documented
None Documented
12 hours (terminal elimination half-life; clinical context: twice-daily dosing needed for continuous effect).
Promethazine: 9-16 h (adults); prolonged in hepatic impairment. Phenylephrine: 2-3 h (oral); 5-10 min (IV due to rapid redistribution). Codeine: 2.5-3.5 h; active metabolites (morphine) 2-3 h.
Renal (approximately 50% as unchanged drug, 30% as metabolites); biliary/fecal elimination accounts for <10%.
Promethazine: ~70% renal as metabolites, minor biliary/fecal. Phenylephrine: ~86-96% renal as metabolites (sulfate and glucuronide conjugates). Codeine: ~90% renal, primarily as morphine and norcodeine conjugates; 5-10% unchanged. Fecal excretion minimal.
Category A/B
Category A/B
Antihistamine / Mast Cell Stabilizer
Antihistamine / Antiemetic